ReviewLangenbeck's archives of surgery2008
Molecular markers of pancreatic cancer: development and clinical relevance.
Review in Langenbeck's archives of surgery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis.Disease markers · 2014Pooled it
- Review
- An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer.Biochemical genetics · 2021Article
- Identification of diagnostic upper gastrointestinal cancer tissue type-specific urinary biomarkers.Biomedical reports · 2019Article
- Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2017Article
- FAK and paxillin, two potential targets in pancreatic cancer.Oncotarget · 2016Review
- Developments in miRNA gene signaling pathways in pancreatic cancer.Future oncology (London, England) · 2016Review
- The promise of methylation on beads for cancer detection and treatment.Expert review of molecular diagnostics · 2014Review
- Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.Archives of pathology & laboratory medicine · 2014Article
- Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis.International journal of clinical and experimental medicine · 2014Article
- The Association between Survival and the Pathologic Features of Periampullary Tumors Varies over Time.HPB surgery : a world journal of hepatic, pancreatic and biliary surgery · 2014Article
- Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Novel methylation biomarker panel for the early detection of pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.Pathology oncology research : POR · 2013Article
- Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy.Journal of hematology & oncology · 2012Article
- Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Cancer letters · 2012Review
- Advances in biomarker research for pancreatic cancer.Current pharmaceutical design · 2012Review
- Study on chronic pancreatitis and pancreatic cancer using MRS and pancreatic juice samples.World journal of gastroenterology · 2011Article
- Proteomics in pancreatic cancer research.International journal of proteomics · 2011Article
- Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.Journal of cancer research and clinical oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of pancreatic cancer remains poor, mainly because of its aggressive biological behaviour and late clinical diagnosis, which precludes the application of appropriate curative therapies. Therefore, one of the major goals in clinical pancreatology is to find molecular markers, specific and sensitive enough to make an early and correct diagnosis of pancreatic cancer, before it has disseminated and become untreatable.
objectiveThis overview article explores the potential utility of current molecular markers for the diagnosis of pancreatic cancer.
resultsThere is a wide array of serum-based and tissue-based markers for pancreatic cancer. Serum-based molecular markers include CA 19-9, CA 125, M2-PK and secreted proteins. A tissue can be used to test genetic mutations such as K-ras, inactivation of tumour suppressor genes (e.g. p16, p53), mucins, telomerase activity, growth factors, DNA methylation, and global gene expression of cDNA microarrays, mitochondrial mutations and proteomics. None of these markers is currently useful for the detection of early pancreatic cancer. In clinical practice, the most commonly accepted use of CA 19-9 is to assess the prognosis and monitor the response to therapy.
conclusionsMany molecular markers have been proposed for the early diagnosis of PC, but most are not ready to be included as part of the routine diagnostic algorithm because they still lack sensitivity, specificity or reproducibility. CA 19-9 remains the most useful molecular marker for the diagnosis and follow-up of clinically and radiological evident pancreatic cancer.
Indexed as
Identifiers
18266003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.